Skip to main content

Table 1 Patient baseline characteristics

From: Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial

Characteristic

All Randomized

(Nā€‰=ā€‰533)

Minimal Contact enrollment

(Nā€‰=ā€‰306)

Acute Episodic Care enrollment

(Nā€‰=ā€‰227)

p-value#

Enrollment Locationā€”no. (%)

Ā Ā Ā Ā 

ā€ƒEmergency department visit

95 (17.8)

-

95 (41.9)

Ā 

ā€ƒUrgent care visit

23 (4.3)

-

23 (10.1)

Ā 

ā€ƒMonoclonal antibody or COVID clinic visit

88 (16.5)

-

88 (38.8)

Ā 

ā€ƒOther urgent clinic visits

21 (3.9)

-

21 (9.3)

Ā 

ā€ƒLow/No- Touch enrollment

306 (57.4)

306 (100.0)

-

Ā 

Median time from COVID test to randomization (IQR)ā€”days

6.0 (3.0, 10.0)

9.0 (5.0, 12.0)

3.0 (1.0, 6.0)

<ā€‰0.001

Participants who initiated trial treatmentā€“no.

458

280

178

Ā 

ā€ƒMedian time from COVID test to

ā€ƒtreatment initiation (IQR)ā€”days

11.0 (7.0, 14.0)

13.0 (10.0, 15.0)

8.0 (5.0, 11.0)

<ā€‰0.001

ā€ƒMedian time from randomization to

ā€ƒtreatment initiation (IQR)ā€”days

3.0 (2.0, 5.0)

3.0 (2.0, 5.0)

3.0 (2.0, 5.0)

0.62

Median age (IQR*)ā€”yr

54.0 (46.0, 59.0)

52.0 (45.0, 58.0)

55.0 (48.0, 60.0)

0.005

Sexā€”no. (%)

Ā Ā Ā Ā 

ā€ƒFemale

311 (58.4)

183 (59.8)

128 (56.4)

0.43

ā€ƒMale

222 (41.7)

123 (40.2)

99 (43.6)

Ā 

Race / ethnicity ā€”no. (%)

Ā Ā Ā Ā 

ā€ƒBlack non-Hispanic

61 (11.4)

19 (6.2)

42 (18.9)

<ā€‰0.001

ā€ƒHispanic

98 (18.4)

32 (10.5)

66 (29.1)

Ā 

ā€ƒWhite non-Hispanic

339 (63.6)

231 (75.5)

108 (47.6)

Ā 

ā€ƒOther**

35 (6.6)

24 (7.8)

11 (4.9)

Ā 

Region-no (%)

Ā Ā Ā Ā 

ā€ƒNortheast

47 (8.8)

40 (13.1)

7 (3.1)

<ā€‰0.001

ā€ƒMidwest

77 (14.5)

37 (12.1)

40 (17.6)

Ā 

ā€ƒSouth

236 (44.3)

59 (19.3)

177 (78.0)

Ā 

ā€ƒWest

173 (32.5)

170 (55.6)

3 (1.3)

Ā 

Median body mass index (IQR)ā€”kg/m2

30.1 (26.0, 35.4)

29.3 (25.5, 33.9)

31.4 (27.3, 37.7)

<ā€‰0.001

History of DVT or PE ā€“ no. (%)

19 (3.6)

12 (3.9)

7 (3.1)

0.61

Hypertensionā€”no. (%)

179 (33.6)

82 (26.8)

97 (42.7)

<ā€‰0.001

Diabetesā€”no. (%)

102 (19.1)

43 (14.1)

59 (26.0)

<ā€‰0.001

History of smokingā€”no. (%)

120 (22.5)

65 (21.2)

55 (24.2)

0.41

Median Platelet count (IQR)ā€”per mm [3]

239.0 (189.0, 307.0)

274.0 (215.0, 329.0)

211.5 (169.0, 251.0)

<ā€‰0.001

Median creatinine clearance (IQR)ā€”mg/ml/1.73m2

114.5 (91.3, 144.6)

113.0 (91.4, 144.7)

117.0 (91.0, 144.4)

0.5

D-dimerā€”no. (%)***

478

264

214

Ā 

ā€ƒā‰¤1 X upper limit of normal

313 (65.5)

174 (65.9)

139 (65.0)

0.82

ā€ƒ>1 - ā‰¤2 X upper limit of normal

115 (24.1)

61 (23.1)

54 (25.2)

Ā 

ā€ƒ>2 X upper limit of normal

50 (10.5)

29 (11.0)

21 (9.8)

Ā 

Median hsCRP (IQR)ā€”mg/L

4.0 (1.5, 12.5)

3.0 (1.3, 10.0)

6.0 (1.9, 31.3)

<ā€‰0.001

  1. *IQR denotes interquartile range. **Other includes American Indian, Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and unknown. ***D-dimer assays varied from site to site. Upper limit of normal was captured for each site with individual participant results compared to local values to determine if within the normal range or elevated above the normal range.
  2. # p-values comparing characteristics in the Minimal Contact enrollment to those in the Acute Episodic Care enrollment group are based on Wilcoxon rank-sum statistics for continuous variables and chi-square statistics for categorical variables.